1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Lung Cancer – Pipeline Review, H1 2013

Metastatic Lung Cancer – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 38 pages

Metastatic Lung Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Metastatic Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Metastatic Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Lung Cancer.
- A review of the Metastatic Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Lung Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Lung Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Metastatic Lung Cancer - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Lung Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Lung Cancer 7
Metastatic Lung Cancer Therapeutics under Development by Companies 9
Metastatic Lung Cancer Therapeutics under Investigation by Universities/Institutes 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Metastatic Lung Cancer Therapeutics - Products under Development by Companies 13
Metastatic Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Metastatic Lung Cancer Therapeutics Development 15
The University of Texas M. D. Anderson Cancer Center 15
Targa Therapeutics Corp. 16
Metastatic Lung Cancer - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
CpG DNA Lipoplex - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
VEGF/rGel - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
CNVN-202 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
aldesleukin - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Sticky siRNA - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
DT-310 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Metastatic Lung Cancer Therapeutics - Drug Profile Updates 30
Metastatic Lung Cancer Therapeutics - Discontinued Products 31
Metastatic Lung Cancer Therapeutics - Dormant Products 32
Metastatic Lung Cancer - Product Development Milestones 33
Featured News and Press Releases 33
Aug 13, 2012: Health Canada Approves TARCEVA As First-Line Therapy For Treatment Of Non-Small Cell Lung Cancer 33
Jun 20, 2011: Momenta Announces Publication Of Preclinical Results Of Oncology Drug M402 In PLoS One 34
Jun 10, 2011: CureVac Presents Promising New Data For Lung Cancer Vaccine CV9201 At ASCO Conference 34
May 19, 2011: VBL Therapeutics Presents Preclinical Data For VB-111 At 14th Annual ASGCT Meeting 35
Nov 10, 2010: Silence Reports Positive Preclinical Research Findings Of Atu027 In Pulmonary Metastasis Animal Models 35
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38



List of Tables

Number of Products Under Development for Metastatic Lung Cancer, H1 2013 7
Products under Development for Metastatic Lung Cancer - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Targa Therapeutics Corp., H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Metastatic Lung Cancer Therapeutics - Drug Profile Updates 30
Metastatic Lung Cancer Therapeutics - Discontinued Products 31
Metastatic Lung Cancer Therapeutics - Dormant Products 32



List of Figures

Number of Products under Development for Metastatic Lung Cancer, H1 2013 7
Products under Development for Metastatic Lung Cancer - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila ...

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline ...

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.